



Adverum Biotechnologies to Present Additional Data from the OPTIC Phase 1 Trial with ADV-022 Intravitreal Gene Therapy in Wet AMD at the Angiogenesis, Exudation, and Degeneration 2020 Meeting

January 28, 2020

-- Presentation of 24-week data from the second cohort and an update from first cohort of patients in the OPTIC trial at Angiogenesis Meeting on Saturday, February 8, 2020 at 2:28 pm EST --

-- Company to host and webcast a discussion with key opinion leaders on Sunday, February 9, at 10:00 am EST --

REDWOOD CITY, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- [Adverum Biotechnologies, Inc.](https://www.adverum.com) (Nasdaq: ADV-022), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of 24-week data from the second cohort of patients (n=6; 2×10^{11} vg/eye) as well as an update from the first cohort of patients (n=6; 6×10^{11} vg/eye) in the OPTIC Phase 1 clinical trial of ADV-022 intravitreal gene therapy in wet AMD at the Angiogenesis, Exudation, and Degeneration 2020 Meeting.

Oral Presentation Details:

Event: Angiogenesis, Exudation, and Degeneration 2020 Meeting

Title: Phase 1 Study of Intravitreal Gene Therapy with ADV-022 for Neovascular AMD (OPTIC Trial)

Session: Session VII: Treatments for Neovascularization in AMD and ROP

Date: February 8, 2020

Time: 2:28 pm EST

Location: Mandarin Oriental Hotel, Miami, FL

Speaker: David S. Boyer, M.D., senior partner, Retina-Vitreous Associates Medical Group and adjunct clinical professor of ophthalmology with the University of Southern California/Keck School of Medicine in Los Angeles, California.

Adverum plans to issue a press release relating to the presentation and post the presentation on Adverum's website at www.adverum.com in the Investors section under the [Events and Presentations](#) page at the beginning of the data presentation at Angiogenesis.

KOL Event Details:

In addition, Adverum will host an event with expert retinal specialists to discuss the OPTIC data presented at Angiogenesis and the potential opportunity for ADV-022. The discussion will be held on Sunday, February 9, 2020 beginning at 10:00 am EST. The event will be webcast live from Adverum's website at www.adverum.com in the Investors section under the [Events and Presentations](#) page. A replay of the webcast will be archived and available for replay following the event.

About Adverum Biotechnologies

Adverum Biotechnologies (Nasdaq: ADV-022) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADV-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. For more information, please visit www.adverum.com.

Investor and Media Inquiries:

Investors:

Myesha Lacy

Adverum Biotechnologies, Inc.

mlacy@adverum.com

1-650-649-1257

Media:

Cherilyn Cecchini, M.D.

LifeSci Communications

ccecchini@lifescicomms.com

1-646-876-5196



Source: Adverum Biotechnologies, Inc.